Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents

Journal of Clinical Psychiatry

Volumn 63, Issue 10, 2002, Pages 854-855

  Stahl, Stephen M ^a  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANXIOLYTIC AGENT; GABAERGIC RECEPTOR AFFECTING AGENT; SEROTONIN; SEROTONIN AGONIST;

AMYGDALOID NUCLEUS; ANXIETY NEUROSIS; DRUG MECHANISM; DRUG POTENTIATION; FEAR; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; NEUROMODULATION; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SHORT SURVEY;

EID: 0036775744     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1001     Document Type: Short Survey

References (6)

1. Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorders. J Clin Psychiatry 2002;63:656-657
2. Stahl SM. Essential Psychopharmacology. 2nd Ed. New York, NY: Cambridge University Press; 2000
3. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505
4. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998;44:1264-1276
5. Stutzmann GE, LeDoux JE. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: A mechanism for modulation of sensory inputs to fear conditioning. J Neurosci 1999;19:RC8
6. Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-686